BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 872076)

  • 21. Immunity to tumor-associated antigens in vasectomized men.
    Anderson DJ; Alexander NJ; Fulgham DL; Vandenbark AA; Burger DR
    J Natl Cancer Inst; 1982 Sep; 69(3):551-5. PubMed ID: 6180209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of tamoxifen and high-dose medroxyprogesterone acetate (MPA) on cell-mediated immune functions in breast cancer patients.
    Mallmann P; Dietrich K; Krebs D
    Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):699-706. PubMed ID: 2151629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Corynebacterium parvum: antibodies measured with the enzyme-linked immunosorbent assay (ELISA) in normal human sera and sera from cancer patients undergoing treatment.
    Ruitenberg EJ; Buys J; Ursem PS
    Ann Immunol (Paris); 1982; 133D(3):305-11. PubMed ID: 7165281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Skin reactions to antigens of propionibacterium acnes in patients with acne vulgaris treated with autovaccine].
    Załuga E
    Ann Acad Med Stetin; 1998; 44():65-85. PubMed ID: 9857532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
    Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
    J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and Corynebacterium parvum.
    Gusdon JP; Homesley HD; Jobson VW; Muss HB
    Obstet Gynecol; 1983 Dec; 62(6):728-35. PubMed ID: 6633998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomodulation by cancer chemotherapeutic agents and antineoplastic activity.
    Spreafico F; Mantovani A
    Pathobiol Annu; 1981; 11():177-95. PubMed ID: 6460217
    [No Abstract]   [Full Text] [Related]  

  • 28. Experiences with leukocyte adherence inhibition in human cancer.
    Maluish AE
    Cancer Res; 1979 Feb; 39(2 Pt 2):644-8. PubMed ID: 367590
    [No Abstract]   [Full Text] [Related]  

  • 29. [The function of the immune system after the treatment of pediatric malignant diseases].
    Gadó J; Schlick B; Bárány O; Németh J; Müller J; Csóka M; Constantin T; Vonnák E; Böcskei R; Hauser P; Kovács G
    Orv Hetil; 2006 Sep; 147(36):1731-8. PubMed ID: 17087017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
    Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Monitoring natural killer cell activity in the blood of patients with malignant pleural effusion after intrapleural administration of Corynebacterium parvum].
    Marel M; Pospísil M; Fiserová A; Melínová L; Skácel Z; Bednár M
    Cas Lek Cesk; 1990 Apr; 129(16):498-500. PubMed ID: 2340567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical studies with Corynebacterium parvum.
    Mitcheson HD; Castro JE
    Dev Biol Stand; 1977 Apr 13-15; 38():509-14. PubMed ID: 344105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trial with Corynebacterium parvum.
    Medenica R; Girard JP; Maurice P
    Dev Biol Stand; 1977 Apr 13-15; 38():483-5. PubMed ID: 344103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hemosorption as a method of unblocking immunotherapy].
    Bilynskiĭ BT; Ts'olko RN; Shnittser IuM
    Vopr Onkol; 1986; 32(6):87-92. PubMed ID: 3727488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The immunotherapy of cancer.
    Parker CW
    Pharmacol Rev; 1973 Jun; 25(2):325-42. PubMed ID: 4581047
    [No Abstract]   [Full Text] [Related]  

  • 37. [Comparative study of the third party and paternal leukocyte immunization in recurrent spontaneous abortion of lowered maternal-fetal immuno-recognition].
    Li D; Li C; Zhu Y
    Zhonghua Fu Chan Ke Za Zhi; 1998 Oct; 33(10):597-600. PubMed ID: 10806684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Leukocyte adherence inhibition test in tumor patients].
    Martínez Martínez B; Ordóñez Gallego A; Juárez Alonso S; González Barón M; Montero García JM
    Rev Esp Oncol; 1982; 29(4):735-42. PubMed ID: 6927371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
    Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
    Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The immunology of cancer: avenues to immunotherapy.
    Woods AH
    Ariz Med; 1973 Jul; 30(7):463-83. PubMed ID: 4581414
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.